Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ENGN | 8-K | bearish | 6/10 | enGene Therapeutics reported Q2 2026 results with a net loss of $0.43/share, beating consensus of -$0.48, but announced | Jun 15, 2026 |
| NTLA | 8-K | bullish | 7/10 | Intellia reported additional positive Phase 3 HAELO results for lonvo-z (CRISPR gene editing candidate) in hereditary an | Jun 15, 2026 |
| SLBT | 6-K | neutral | 5/10 | SL Science Holding Ltd (SLBT) announced the closing of its business combination with SPAC Horizon Space Acquisition II C | Jun 15, 2026 |
| SNSE | 8-K | bearish | 6/10 | Sensei Biotherapeutics (SNSE) filed an 8-K confirming its name change to Faeth Therapeutics (ticker FTH effective June 1 | Jun 15, 2026 |
| NMRA | 8-K | bearish | 7/10 | Neumora Therapeutics announced that its Phase 3 KOASTAL-2 and -3 studies of navacaprant for major depressive disorder fa | Jun 15, 2026 |
| OPK | PRESS-RELEASE | neutral | 3/10 | OPKO Health presented preclinical data for OPK8801001, a long-acting hGH receptor antagonist for acromegaly, at ENDO 202 | Jun 15, 2026 |
| SYRE | 8-K | bullish | 7/10 | Spyre Therapeutics announced positive 12-week induction topline data from Part A of the Phase 2 SKYLINE trial of SPY002 | Jun 15, 2026 |
| AIM | 8-K | bullish | 5/10 | AIM ImmunoTech received formal notice from NYSE American that it has regained compliance with continued listing standard | Jun 15, 2026 |
| TELO | 8-K | neutral | 3/10 | Telomir Pharmaceuticals announced a peer-reviewed publication of preclinical data for Telomir-Zn in a zebrafish model of | Jun 15, 2026 |
| PDSB | 8-K | neutral | 2/10 | PDS Biotechnology Corp filed an 8-K to announce that its 2026 Annual Meeting of Stockholders is scheduled for August 10, | Jun 15, 2026 |
| MEHA | 8-K | bearish | 7/10 | Functional Brands Inc. received a Nasdaq Staff Delisting Determination because its common stock closed at $0.10 or less | Jun 15, 2026 |
| APTOF | 8-K | bullish | 7/10 | Aptose Biosciences presented updated Phase 1/2 TUSCANY trial data for tuspetinib (TUS) triplet therapy in newly diagnose | Jun 15, 2026 |
| LEGN | 6-K | bullish | 7/10 | Legend Biotech announced first clinical proof-of-concept data for LB2501, its in vivo CD19/CD20 dual-targeting CAR-T the | Jun 15, 2026 |
| AAPG | 6-K | bullish | 6/10 | Ascentage Pharma presented 17 clinical updates at the EHA2026 Congress, including data from its two core assets olveremb | Jun 15, 2026 |
| NVO | 6-K | neutral | 3/10 | Novo Nordisk filed a routine 6-K disclosing weekly share repurchase transactions under its existing DKK 15 billion buyba | Jun 15, 2026 |
| LXEO | 8-K | bullish | 6/10 | Lexeo Therapeutics finalized the SUNRISE-FA 2 pivotal trial protocol for LX2006 in Friedreich ataxia cardiomyopathy, wit | Jun 15, 2026 |
| LFCR | PRESS-RELEASE | bullish | 6/10 | Lifecore Biomedical announced a new commercial manufacturing agreement with an unnamed global pharmaceutical company for | Jun 15, 2026 |
| ELTP | 8-K | bullish | 5/10 | Elite Pharmaceuticals reported positive results from a pivotal bioequivalence study for an undisclosed anticonvulsant ge | Jun 15, 2026 |
| AXSM | PRESS-RELEASE | neutral | 3/10 | Axsome Therapeutics presented new data on AXS-12 and solriamfetol at SLEEP 2026, including cognitive/functional outcomes | Jun 15, 2026 |
| TNXP | CLUSTER | neutral | 3/10 | Three insiders including CEO Seth Lederman made small open-market purchases totaling $132K, representing ~0.07% of TNXP' | Jun 15, 2026 |
| XRTX | 6-K | neutral | 4/10 | XORTX Therapeutics filed a 6-K announcing the appointment of Mika Grasso as Co-CEO and providing a corporate update on i | Jun 15, 2026 |
| TLSA | 6-K | bullish | 4/10 | Executive Chairman and Founder Gabriele Cerrone, through Panetta Partners Ltd, purchased 15,000 common shares at $1.11 p | Jun 15, 2026 |
| AZN | 6-K | bullish | 7/10 | AstraZeneca announced FDA approval of Truqap (capivasertib) in combination with abiraterone and prednisone as the first | Jun 15, 2026 |
| PHVS | PRESS-RELEASE | bullish | 7/10 | Pharvaris presented positive Phase 3 RAPIDe-3 data at EAACI 2026, showing deucrictibant achieved a median time to onset | Jun 15, 2026 |
| SCNI | 6-K | bearish | 6/10 | Scinai reported Q1 2026 revenue of $489K (down 16.5% YoY) and an operating loss of $2.5M (widened from $1.6M). Net incom | Jun 15, 2026 |
| CNTX | PRESS-RELEASE | bullish | 7/10 | Context Therapeutics reported positive interim Phase 1 data for its CLDN6 x CD3 TCE bispecific antibody, CTIM-76, showin | Jun 15, 2026 |
| FLNA | 8-K | neutral | 3/10 | Filana Therapeutics held its 2026 Annual Meeting on June 11, 2026, where shareholders approved Amendment No. 2 to the 20 | Jun 15, 2026 |
| SVA | 6-K | bearish | 6/10 | Sinovac regained Nasdaq listing compliance following the long-delayed filing of its FY2025 20-F on June 5, 2026, which c | Jun 15, 2026 |
| RDY | 6-K | bullish | 6/10 | Dr. Reddy's announced the first-to-market launch of Bosutinib Tablets 400mg (generic Bosulif) in the U.S., a tyrosine ki | Jun 15, 2026 |
| ATHE | 6-K | neutral | 2/10 | Alterity Therapeutics filed two 6-K reports on June 15, 2026, each containing an exhibit: one notification of cessation | Jun 15, 2026 |